International Clinical Trial: Prospective, Open-Label, Single-Center Clinical Study of Iparomlimab and Tuvonralimab Combined with AG Regimen plus SBRT versus Epalolitovorimab Combined with AG Regimen as First-Line Treatment for Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115120) titled 'Prospective, Open-Label, Single-Center Clinical Study of Iparomlimab and Tuvonralimab Combined with AG Regimen plus SBRT versus Epalolitovorimab Combined with AG Regimen as First-Line Treatment for Unresectable Locally Advanced or Metastatic Pancreatic Cancer' on Dec. 23, 2025.

Study Type: Interventional study

Study Design: Non randomized control

Primary Sponsor: The First Affiliated Hospital of University of science and technology of China

Condition: Pancreatic cancer

Intervention: Cohort 1:Iparomlimab and Tuvonralimab+albumin-bound paclitaxel + gemcitabine+SBRT

Recruitment Status: Not Recruiting

Phase...